Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURACVE:GPHNYSEMKT:IGCNYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.83+4.9%$6.39$4.84▼$12.38$279.25M0.43202,337 shs161,112 shsGPHGraphite OneC$0.84C$0.93C$0.55▼C$1.07C$85.05M1.0260,338 shs28,990 shsIGCIGC Pharma$0.30-8.3%$0.30$0.25▼$0.63$21.52M1.45358,961 shs214,616 shsOGNOrganon & Co.$12.94-1.7%$13.71$10.45▼$23.10$3.36B0.732.75 million shs5.42 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+0.91%-2.63%-12.30%-29.80%-25.87%GPHGraphite One-1.18%-10.64%-11.58%-3.45%+18.31%IGCIGC Pharma-0.34%+4.21%+0.34%-8.33%+29,699,900.00%OGNOrganon & Co.+3.74%+17.39%-9.02%-16.66%-30.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.3447 of 5 stars3.62.00.00.02.92.50.0GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.2044 of 5 stars3.50.00.00.00.01.70.0OGNOrganon & Co.4.7679 of 5 stars3.21.03.33.73.41.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.75290.22% UpsideGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,195.99% UpsideOGNOrganon & Co. 2.33Hold$19.7552.63% UpsideCurrent Analyst Ratings BreakdownLatest AURA, OGN, GPH, and IGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/6/2025IGCIGC PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.502/24/2025IGCIGC PharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $4.252/14/2025OGNOrganon & Co.BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.002/14/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.001/31/2025AURAAura BiosciencesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.24M19.28N/AN/A$0.08 per share3.74OGNOrganon & Co.$6.40B0.53$4.15 per share3.12($0.27) per share-47.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$76.41M-$1.75N/AN/AN/AN/A-41.57%-36.43%5/8/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AOGNOrganon & Co.$864M$3.333.893.460.9013.49%431.62%8.03%5/1/2025 (Estimated)Latest AURA, OGN, GPH, and IGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AURAAura Biosciences-$0.45N/AN/AN/AN/AN/A5/1/2025Q1 2025OGNOrganon & Co.$0.92N/AN/AN/A$1.53 billionN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$1.128.66%+25.99%33.63%N/ALatest AURA, OGN, GPH, and IGC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.4712.47GPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98OGNOrganon & Co.17.731.701.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%GPHGraphite One0.07%IGCIGC Pharma3.87%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%GPHGraphite One28.81%IGCIGC Pharma31.48%OGNOrganon & Co.1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.23 million47.25 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionableAURA, OGN, GPH, and IGC HeadlinesRecent News About These CompaniesOrganon Q1 2025 Earnings PreviewApril 30 at 6:36 PM | msn.comOrganon & Co. (NYSE:OGN) Trading 4.6% Higher - Time to Buy?April 30 at 2:11 PM | marketbeat.comBoothbay Fund Management LLC Raises Holdings in Organon & Co. (NYSE:OGN)April 30 at 6:21 AM | marketbeat.comOxford Asset Management LLP Invests $419,000 in Organon & Co. (NYSE:OGN)April 29 at 6:34 AM | marketbeat.comRaymond James Financial Inc. Invests $4.19 Million in Organon & Co. (NYSE:OGN)April 29 at 3:42 AM | marketbeat.comCountdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPSApril 28 at 10:21 AM | zacks.com43,531 Shares in Organon & Co. (NYSE:OGN) Bought by Dark Forest Capital Management LPApril 28 at 5:08 AM | marketbeat.comFirst Trust Advisors LP Sells 34,179 Shares of Organon & Co. (NYSE:OGN)April 28 at 4:27 AM | marketbeat.comXTX Topco Ltd Lowers Position in Organon & Co. (NYSE:OGN)April 28 at 3:58 AM | marketbeat.comEnvestnet Asset Management Inc. Has $3.61 Million Position in Organon & Co. (NYSE:OGN)April 27 at 3:16 AM | marketbeat.comOrganon & Co. (OGN) to Release Earnings on ThursdayApril 26, 2025 | marketbeat.comOrganon (OGN) Ascends But Remains Behind Market: Some Facts to NoteApril 25, 2025 | zacks.comOrganon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItApril 25, 2025 | zacks.comAnalysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out forApril 24, 2025 | zacks.comOrganon & Co. (NYSE:OGN) Hits New 12-Month Low - Time to Sell?April 24, 2025 | marketbeat.comBridgewater Associates LP Reduces Stake in Organon & Co. (NYSE:OGN)April 23, 2025 | marketbeat.comOrganon & Co. (NYSE:OGN) Holdings Raised by Wells Fargo & Company MNApril 23, 2025 | marketbeat.com42,149 Shares in Organon & Co. (NYSE:OGN) Acquired by Sharpepoint LLCApril 22, 2025 | marketbeat.comShort Interest in Organon & Co. (NYSE:OGN) Declines By 17.6%April 22, 2025 | marketbeat.comOrganon (OGN) Receives a Sell from Bank of America SecuritiesApril 22, 2025 | markets.businessinsider.comSterling Capital Management LLC Reduces Stock Position in Organon & Co. (NYSE:OGN)April 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Dave & Buster’s Stock: A Short-Squeeze PLAY for Q2By Thomas Hughes | April 10, 2025View Dave & Buster’s Stock: A Short-Squeeze PLAY for Q2First Watch Restaurant Group: A First-Rate Small-Cap Growth StockBy Thomas Hughes | April 3, 2025View First Watch Restaurant Group: A First-Rate Small-Cap Growth StockBig Buybacks: 3 Large Caps Exceed 5% Repurchase PowerBy Leo Miller | April 3, 2025View Big Buybacks: 3 Large Caps Exceed 5% Repurchase PowerAURA, OGN, GPH, and IGC Company DescriptionsAura Biosciences NASDAQ:AURA$5.83 +0.27 (+4.86%) As of 04:00 PM EasternAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Graphite One CVE:GPHC$0.84 0.00 (0.00%) As of 03:40 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.30 -0.03 (-8.31%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Organon & Co. NYSE:OGN$12.94 -0.22 (-1.67%) As of 03:59 PM EasternOrganon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
